SCHEMBL251801

SCHEMBL251801

O=[N+]([O-])c1ncccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.45
ALDH1A1 P00352 5/20 0.45
POLB P06746 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 3/20 0.45
IDO1 P14902 2/20 0.45
TDO2 P48775 2/20 0.45
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
PKM P14618 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
CASP6 P55212 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
PDE10A Q9Y233 1/20 0.43
MAPK1 P28482 2/20 0.42
S1PR4 O95977 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29577484 1.00 MAPT (0.45) MAPTALDH1A1POLBL3MBTL1MEN1
Benzene SCHEMBL28231880 0.98 MEN1 (0.45) MAPTALDH1A1POLBL3MBTL1MEN1
SCHEMBL294121 0.77 PDE10A (0.58) MAPTALDH1A1POLBL3MBTL1MEN1
SCHEMBL29579675 0.77 PDE10A (0.58) MAPTALDH1A1POLBL3MBTL1MEN1
SCHEMBL5643188 0.77 PDE10A (0.48) MAPTALDH1A1POLBL3MBTL1MEN1
SCHEMBL488820 0.76 KMT2A (0.58) MAPTALDH1A1POLBL3MBTL1MEN1
SCHEMBL541486 0.75 NPC1 (0.51) MAPTALDH1A1POLBL3MBTL1MEN1
SCHEMBL799695 0.75 ALDH1A1 (0.51) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL21847263 0.75 KMT2A (0.43) MAPTALDH1A1POLBL3MBTL1MEN1
SCHEMBL601835 0.75 HTT (0.50) MAPTALDH1A1POLBL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240391874-A1 NOVEL, SAFE, ECONOMICAL AND AN EFFICIENT PROCESS FOR PREPARATION OF 3-FLUORO-2-NITRO PYRIDINE OF FORMULA I AASTRID LIFE SCIENCES PVT. LTD. (IN) 2024-11-28 US claimed
EP-4251612-A1 NOVEL, SAFE, ECONOMICAL AND AN EFFICIENT PROCESS FOR PREPARATION OF 3-FLUORO-2-NITRO PYRIDINE OF FORMULA I Aastrid Life Sciences Pvt. Ltd. (IN) 2023-10-04 EP claimed
WO-2023119308-A1 NOVEL, SAFE, ECONOMICAL AND AN EFFICIENT PROCESS FOR PREPARATION OF 3-FLUORO-2-NITRO PYRIDINE OF FORMULA I AASTRID LIFE SCIENCES PVT. LTD. (IN) 2023-06-29 WO claimed
EP-4746963-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
WO-2026103873-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 杭州百新生物医药科技有限公司 2026-05-21 WO disclosed
EP-4743465-A1 BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-20 EP disclosed
EP-4735430-A1 MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2026-05-06 EP disclosed
US-20260116871-A1 Tyrosine Kinase Inhibitors and Uses Thereof FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) 2026-04-30 US disclosed
WO-2026086911-A1 TYROSINE KINASE INHIBITORS AND USES THEREOF FUJIAN HAIXI PHARMACEUTICALS CO., LTD. (CN) 2026-04-30 WO disclosed
EP-4731207-A2 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2026-04-29 EP disclosed
US-12577228-B2 Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds UCB Biopharma SRL (BE) 2026-03-17 US disclosed
WO-2006044355-A1 TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS AMGEN INC. (US) 2006-04-27 WO disclosed
US-20060025425-A1 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION 2006-02-02 US disclosed
EP-1368342-B1 BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS NEUROGEN CORP (US) 2005-09-07 EP disclosed
US-6916819-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2005-07-12 US disclosed
EP-1368342-A2 BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS NEUROGEN CORPORATION (US) 2003-12-10 EP disclosed
US-20030069257-A1 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION 2003-04-10 US disclosed
WO-2002050062-A2 BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS NEUROGEN CORPORATION (US) 2002-06-27 WO disclosed
US-4225713-A HYPOTENSIVE AGENTS FREED MEIER E 1980-09-30 US disclosed
US-4138564-A HYPOTENSIVE AMERICAN HOME PRODUCTS CORPORATION (US) 1979-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025425-A1 Benzimidazole and pyridylimidazole derivatives GABBR1, GABBR2, GABRA2 MAPT 1046/4885ALDH1A1 470/4885POLB 3712/4885
US-20240391874-A1 NOVEL, SAFE, ECONOMICAL AND AN EFFICIENT PROCESS FOR PREPARATION OF 3-FLUORO-2-NITRO PYRIDINE OF FORMULA I AFF1, SCN1B, AFF2 MAPT 3357/4885ALDH1A1 1077/4885POLB 1048/4885
US-12577228-B2 Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds FCGR2A, FCER2, FCGR1A MAPT 4836/4885ALDH1A1 2200/4885POLB 4668/4885
US-20260116871-A1 Tyrosine Kinase Inhibitors and Uses Thereof ERBB3, SRC, ALK MAPT 4617/4885ALDH1A1 3025/4885POLB 2835/4885
US-20030069257-A1 Benzimidazole and pyridylimidazole derivatives GABBR1, GABRA1, GABBR2 MAPT 977/4885ALDH1A1 220/4885POLB 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.